AsianScientist (May 6, 2013) – Chinese healthcare company Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced this week the joint acquisition of the Caesarea, Israel-based Alma Lasers Ltd. with the Pramerica-Fosun Fund.
Alma Lasers is an international manufacturer of laser, light-based, radiofrequency and ultrasound products with core R&D capabilities are in the medical and aesthetic device manufacturing field. It began doing business in China in 2003, and has already become the market leader in the exclusive field of medical cosmetic lasers. China is also one of the biggest markets for Alma Lasers.
According to a Harris Williams report, Alma Laser captures a 15 percent share of the global market for high-end aesthetic devices with annual turnover near US$100 million.
“Alman team is glad to become one of the members of Fosun Pharma. Fosun Pharma’s previous successful experience in the merger and acquisition and the medical healthcare as well as the medical aesthetic device fields, these strategic development focus will become Alman’s excellent platform in Asia as well as in the World’s business development. We do look forward to cooperating with Fosun Pharma’s management team and benefit from their professional experiences,” said Dr. Ziv Karni, the CEO of Alma.
Fosun Pharma recently completed its H Shares offering and the opening up of the international capital channel. According to Fosun Pharma, the acquisition of Alma Lasers will not exceed US$240 million for a 95.6 percent share in the company.
“We are confident in the growth of the global aesthetics industry, especially in China, Brazil, Russia and India. This represents a huge development space in developing countries. We will continue to support the global business development of Alma Lasers,” said Mr. Chen Qiyu, Chairman of Fosun Pharma.
——
Source: Fosun Pharma.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
